In this webinar, we will explore with Emerging Biopharma companies (EBPs), investors and clinicians how external control arms (ECA) gained from real world data (RWD) can support decision-making in early stages of clinical development of a new compound. Our panelists will discuss how ECAs can help to contextualize single-arm trial results of a new drug obtained in early phases of clinical development. They will also share their perspective on how this contextualization can contribute to guide priorities in drug development and how it can support EBPs in their discussions with investors.

WHAT ATTENDEES WILL LEARN:

• Methodological aspects of external control arms (ECA)
• Key differences between the use of ECA in early phases of clinical development and for regulatory/HTA purposes
• How ECA can guide clinical development of new compounds
• How supplementing early-phase single-arm trials with an ECA can help EBPs differentiate themselves in the race to obtain funding from investors

Speakers:

Benedikt Maissenhaelter
Head of European Oncology Evidence Network, Real World Solutions, IQVIA

Chiara Cantoni
Offering Lead for External Comparator studies, Real World Solutions, IQVIA

Bruno Osterwalder, MD, FFPM
Managing Director, B.O. Consulting GmbH

Philippe Pouletty
Co-Founder, CEO, Truffle Capital

Bettina Ryll, MD, PhD
Founder, Melanopa Patient Network Europe (MPNE)

Gerd Rippin
Senior Director Biostatistics; Real World Solutions, IQVIA